publication date: Apr. 30, 2015
Three Xtandi Trials Show Positive Results In Castration-Resistant Prostate Cancer
Astellas Pharma Inc. and Medivation Inc. presented an updated overall survival analysis from the placebo-controlled phase III trial of Xtandi in chemotherapy-naive metastatic CRPC.
The companies also published data from two separate phase II head-to-head studies, named STRIVE and TERRAIN, comparing Xtandi (enzalutamide) to Casodex (bicalutamide).
The phase III trial, named PREVAIL, was a randomized, double-blind trial that enrolled 1,717 patients at sites in the U.S., Canada, Europe, Australia, Russia, Israel and Asia, including Japan.
The trial enrolled patients with chemotherapy-naive metastatic prostate cancer whose disease progressed on androgen deprivation therapy (i.e., a LHRH therapy or after bilateral orchiectomy).
The co-primary endpoints of the trial were overall survival and radiographic PFS. The trial was designed to evaluate Xtandi at a dose of 160 mg taken orally once daily versus placebo.
The updated overall survival analysis was conducted at 784 deaths and found a statistically significant overall survival benefit with a 23 percent reduction in risk of death (OS: HR 0.77; 95% CI 0.67-0.88; p=0.0002) and a four-month improvement in median survival with Xtandi (35.3 months [95% CI 32.2 – not yet reached]) over placebo (31.3 months [95% CI 28.8 – 34.2]).
As of the June 2014 cut-off date with a median follow-up duration of 31 months: 52 percent of Xtandi and 81 percent of placebo patients received one … Continue reading CCL April – Three Xtandi Trials Show Positive Results In Castration-Resistant Prostate Cancer
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.